SBIR/STTR Research Award

Multiplexed high-content assay for toxicity profiling using live iPSC-derived cardiomyocyte lines with lineage-specific barcoding

Award identifier 9d19a1b61d27313a56dbcdcf99645b2d3a865c922065c4af28b6f1043efa47cbAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$1,999,945

Program and phase

SBIR · Phase II

Award year

2018

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
CAIRN BIOSCIENCES INC
Proposal award date
2018-08-15
Contract end date
2020-07-31
UEI
LWZWY2J1M2J4
Solicitation number
PA17-302
Topic code
100

Research abstract

Project Summary Abstract Human induced pluripotent stem cellshiPSCsare poised to transform toxicological evaluationhowever new approaches to enable their functional and structural profiling are needed to improve the utility of hiPSCbased models for predictive and mechanistic toxicology screeningThis need is addressed by our project s Specific Aims that encompassdevelopment of a novel platform for generation of hiPSC derived reporter cellsgeneration of a panel of multicolor hiPSC derived cardiomyocyteshiPSC CMswith stable lineage specific fluorescent reportersandimplementation and validation of a pilot machine learning enabled predictive cardiotoxicity screen using these toolsThe proposed tools are configured to be extensible to other toxicologyrelevant pathways and phenotypes making it uniquely positioned to capitalize on the growing commercial need for high throughput predictive toxicology assaysThe project deliverables benefit public health by improving the ability to rapidly identify liabilities in specific cardiomyocyte lineage typesthus reducing the time and cost to pinpoint cardiotoxicity of pharmaceutical and environmental chemicals Project Narrative The assay and reagents established in the course of this project directly address the goals of significant initiatives to improve the effectiveness of cardiotoxicity testingsuch as the FDA s CiPA initiative and the work of the Cardiac Safety Research ConsortiumThe resulting improvements in the pace and precision of drug testing will result in public health benefit through the development of more cost effective and safer medicinesBeyond toxicological evaluation of therapeutic compoundsour innovative technology will deliver additional benefit to public health by virtue of its utility in investigating the toxicities of environmental chemicalsin line with the focus of government agencies and initiatives such as the EPA and Toxin the US and EU ToxRisk in Europe

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

9 SBIR/STTR records share this UEI (2015–2021). Reported award amounts total $5,740,087. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services, National Science Foundation

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.